Novus Therapeutics to Present OP0201 Data at the 20th International Symposium on Recent Advances in Otitis Media
- Poster Title: A Phase 1 Safety Study of Repeated Doses of Intranasal OP0201 Metered Dose Inhaler Compared to Placebo in Healthy Adults: A Potential Treatment for Otitis Media
- Date/Time:
Tuesday June 11, 2019 from 1:00 –3:00 PM - Location:
Loews Hollywood Hotel ,Los Angeles, California
About Study C-002
Study C-002 was a phase 1 randomized, double-blind, placebo-controlled,
parallel-group, dose-escalation clinical trial designed to evaluate
safety and tolerability of 14 days of daily intranasal OP0201 (30 mg per
day or 60 mg per day) compared to placebo in 30 healthy adults. The
study was conducted at a single phase 1 unit in
About
Forward-Looking Statements
This press release contains forward‐looking statements that involves
substantial risks and uncertainties. Any statements about the company’s
future expectations, plans and prospects, including statements about its
strategy, future operations, development of its product candidates, and
other statements containing the words “believes,” “anticipates,”
“plans,” “expects,” “estimates,” “intends,” “predicts,” “projects,”
“targets,” “looks forward,” “could,” “may,” and similar expressions,
constitute forward‐looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, although not all
forward‐looking statements include such identifying words.
Forward‐looking statements include, but are not limited to statements
regarding: risks related to market conditions, the completion of the
common stock and warrant financing, including the satisfaction of the
closing conditions, and the use of anticipated proceeds; expectations
regarding the timing for the commencement and completion of product
development or clinical trials, including the four ongoing OP0201
clinical trials; expectations regarding the success of clinical trials;
the rate and degree of market acceptance and clinical utility of the
company’s products; the company’s commercialization, marketing and
manufacturing capabilities and strategy; the company’s intellectual
property position and strategy; the company’s ability to identify
additional products or product candidates with significant commercial
potential; the company’s estimates regarding expenses, future revenue,
capital requirements and needs for additional financing; developments
relating to the company’s competitors and industry; and the impact of
government laws and regulations. Actual results may differ materially
from those indicated by such forward‐looking statements as a result of
various important factors, including: the ability to develop
commercially viable product formulations; the sufficiency of the
company’s cash resources; the ability to obtain necessary regulatory and
ethics approvals to commence additional clinical trials; whether data
from early clinical trials will be indicative of the data that will be
obtained from future clinical trials; whether the results of clinical
trials will warrant submission for regulatory approval of any
investigational product; whether any such submission will receive
approval from the
View source version on businesswire.com: https://www.businesswire.com/news/home/20190610005184/en/
Source:
Investor Contacts
Timothy McCarthy
LifeSci Advisors, LLC
Tel:
212-915-2564
tim@lifesciadvisors.com